Insider Selling: Jazz Pharmaceuticals plc (NASDAQ:JAZZ) EVP Sells 5,000 Shares of Stock

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) EVP Neena M. Patil sold 5,000 shares of the firm’s stock in a transaction dated Friday, May 3rd. The shares were sold at an average price of $109.65, for a total value of $548,250.00. Following the transaction, the executive vice president now owns 36,629 shares of the company’s stock, valued at approximately $4,016,369.85. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Jazz Pharmaceuticals Stock Up 1.2 %

Shares of JAZZ traded up $1.36 during midday trading on Tuesday, hitting $111.21. 841,956 shares of the company’s stock traded hands, compared to its average volume of 617,356. Jazz Pharmaceuticals plc has a 1 year low of $103.01 and a 1 year high of $146.70. The firm’s fifty day moving average is $115.98 and its 200-day moving average is $120.78. The company has a current ratio of 2.27, a quick ratio of 1.90 and a debt-to-equity ratio of 1.38. The stock has a market capitalization of $7.01 billion, a price-to-earnings ratio of 22.65, a price-to-earnings-growth ratio of 1.53 and a beta of 0.63.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings data on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 EPS for the quarter, missing the consensus estimate of $4.44 by ($0.04). Jazz Pharmaceuticals had a net margin of 8.61% and a return on equity of 27.86%. The business had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $1.01 billion. As a group, sell-side analysts anticipate that Jazz Pharmaceuticals plc will post 16.24 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on JAZZ shares. JPMorgan Chase & Co. raised their price objective on Jazz Pharmaceuticals from $170.00 to $190.00 and gave the company an “overweight” rating in a research report on Friday, March 22nd. Royal Bank of Canada restated an “outperform” rating and set a $195.00 price objective on shares of Jazz Pharmaceuticals in a research report on Thursday, February 29th. StockNews.com lowered Jazz Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, May 2nd. Stifel Nicolaus lifted their price target on Jazz Pharmaceuticals from $225.00 to $230.00 and gave the stock a “buy” rating in a research report on Friday, March 15th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $222.00 price target on shares of Jazz Pharmaceuticals in a research report on Thursday, May 2nd. Two investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $192.75.

Hedge Funds Weigh In On Jazz Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Baupost Group LLC MA raised its stake in Jazz Pharmaceuticals by 23.7% in the 4th quarter. Baupost Group LLC MA now owns 833,696 shares of the specialty pharmaceutical company’s stock worth $102,545,000 after acquiring an additional 160,000 shares during the last quarter. International Assets Investment Management LLC purchased a new position in Jazz Pharmaceuticals in the 4th quarter worth $7,201,000. Desjardins Global Asset Management Inc. purchased a new position in Jazz Pharmaceuticals in the 4th quarter worth $1,943,000. Kovack Advisors Inc. raised its stake in Jazz Pharmaceuticals by 347.1% in the 4th quarter. Kovack Advisors Inc. now owns 29,971 shares of the specialty pharmaceutical company’s stock worth $3,686,000 after acquiring an additional 23,267 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale raised its stake in Jazz Pharmaceuticals by 94.2% in the 4th quarter. DekaBank Deutsche Girozentrale now owns 91,540 shares of the specialty pharmaceutical company’s stock worth $11,210,000 after acquiring an additional 44,414 shares during the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.